FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387679102> ?p ?o ?g. }

• W4387679102 abstract "<sec> <title>BACKGROUND</title> COVID-19 is a recent major public health concern caused by the SARS-CoV-2 virus, with approximately 44.6 million COVID-19–positive cases and 530,000 deaths in India (as of February 1, 2023). The COVID-19 vaccination drive in India was initiated in January 2021; however, an effective preventive strategy with high efficacy and immunological safety remains elusive. </sec> <sec> <title>OBJECTIVE</title> The aim of this study is to assess the immunogenic responses of <i>Arsenicum album</i> 30CH (AA30CH) as COVID-19 prophylaxis, including assessment of immunological markers, innate and acquired immune responses, COVID-19 symptoms, and its associated antibody responses. </sec> <sec> <title>METHODS</title> This randomized controlled clinical trial (RCT) will include two parallel comparator groups of AA30CH and placebo with an allocation ratio of 1:1 conducted in the Pathanamthitta district of Kerala, India. The placebo or AA30CH will be administered in three intervention schedules and blood samples will be collected before and after each of the intervention schedules. Based on the inclusion and exclusion criteria, 112 participants per arm (with an expected dropout of 20%) will be screened. Immunogenic responses will be evaluated by determining the antigen density and modulation in immunological markers and lymphocyte subsets CD3, CD4, CD8, CD24, CD27, CD38, CD4 interferon-γ, CD4 CD17, CD4 CD25 (activated T lymphocytes), T cells, B cells, dendritic cells (mature and immature), and natural killer cells on days 1, 5, 23,27, 45, 49, and 66. The innate and acquired immune responses will also be evaluated by a real-time reverse-transcriptase polymerase chain reaction (RT-PCR) array profiler (84-gene set) before and after the study interventions. The toxicity status of AA30CH in study participants will be evaluated through hepatic, renal, and hematological parameters and peripheral smears on days 1, 5, 23, 27, 45, 49, and 66. The number of participants developing COVID-19–like symptoms per National Centre for Disease Control guidelines and the number of participants testing positive for COVID-19 in RT-PCR during follow-ups in any of the three intervention schedules will be identified. Moreover, a subgroup analysis will be used to assess the COVID-19 antibody responses between vaccinated and unvaccinated participants. </sec> <sec> <title>RESULTS</title> This RCT protocol has been approved by various committees and funded by the Central Council for Research in Homoeopathy, Ministry of Ayush, Government of India. The project has been implemented in collaboration with the Department of Homoeopathy, Government of Kerala. The RCT was rolled out on January 25, 2023, and enrollment was completed April 3, 2023. The immunological assays will be conducted at the Department of Biotechnology-Translational Health Science and Technology Institute, Faridabad, India. </sec> <sec> <title>CONCLUSIONS</title> This study will represent the first evaluation of the immunological efficacy and safety of AA30CH in an RCT, which may significantly impact the use of homeopathy as an evidence-based medicine approach. </sec> <sec> <title>CLINICALTRIAL</title> Clinical Trials Registry-India CTRI/2022/08/045089; https://tinyurl.com/mryrpkvk </sec> <sec> <title>INTERNATIONAL REGISTERED REPORT</title> DERR1-10.2196/48479 </sec>" @default.
• W4387679102 created "2023-10-17" @default.
• W4387679102 creator A5005498936 @default.
• W4387679102 creator A5037908729 @default.
• W4387679102 creator A5057175750 @default.
• W4387679102 creator A5072439294 @default.
• W4387679102 creator A5092162751 @default.
• W4387679102 creator A5092871963 @default.
• W4387679102 creator A5092871964 @default.
• W4387679102 creator A5092871965 @default.
• W4387679102 date "2023-04-25" @default.
• W4387679102 modified "2023-10-17" @default.
• W4387679102 title "Immunological Responses of Arsenicum album 30CH to Combat COVID-19: Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial in the Pathanamthitta District of Kerala (Preprint)" @default.
• W4387679102 cites W1983944773 @default.
• W4387679102 cites W2084625614 @default.
• W4387679102 cites W2239646043 @default.
• W4387679102 cites W2321337665 @default.
• W4387679102 cites W2908772122 @default.
• W4387679102 cites W3001118548 @default.
• W4387679102 cites W3009582878 @default.
• W4387679102 cites W3012565918 @default.
• W4387679102 cites W3018517500 @default.
• W4387679102 cites W3029830049 @default.
• W4387679102 cites W3030745412 @default.
• W4387679102 cites W3038063455 @default.
• W4387679102 cites W3047996214 @default.
• W4387679102 cites W3049647325 @default.
• W4387679102 cites W3089021428 @default.
• W4387679102 cites W3110466220 @default.
• W4387679102 cites W3127240052 @default.
• W4387679102 cites W3215191450 @default.
• W4387679102 cites W3215579787 @default.
• W4387679102 cites W4205225613 @default.
• W4387679102 cites W4221077375 @default.
• W4387679102 cites W4229332040 @default.
• W4387679102 cites W4292622968 @default.
• W4387679102 cites W4296627425 @default.
• W4387679102 cites W4301187553 @default.
• W4387679102 cites W4308706077 @default.
• W4387679102 cites W7429656 @default.
• W4387679102 doi "https://doi.org/10.2196/preprints.48479" @default.
• W4387679102 hasPublicationYear "2023" @default.
• W4387679102 type Work @default.
• W4387679102 citedByCount "0" @default.
• W4387679102 crossrefType "posted-content" @default.
• W4387679102 hasAuthorship W4387679102A5005498936 @default.
• W4387679102 hasAuthorship W4387679102A5037908729 @default.
• W4387679102 hasAuthorship W4387679102A5057175750 @default.
• W4387679102 hasAuthorship W4387679102A5072439294 @default.
• W4387679102 hasAuthorship W4387679102A5092162751 @default.
• W4387679102 hasAuthorship W4387679102A5092871963 @default.
• W4387679102 hasAuthorship W4387679102A5092871964 @default.
• W4387679102 hasAuthorship W4387679102A5092871965 @default.
• W4387679102 hasConcept C10205521 @default.
• W4387679102 hasConcept C126322002 @default.
• W4387679102 hasConcept C142724271 @default.
• W4387679102 hasConcept C159654299 @default.
• W4387679102 hasConcept C159912055 @default.
• W4387679102 hasConcept C167672396 @default.
• W4387679102 hasConcept C168563851 @default.
• W4387679102 hasConcept C203014093 @default.
• W4387679102 hasConcept C204787440 @default.
• W4387679102 hasConcept C22070199 @default.
• W4387679102 hasConcept C27081682 @default.
• W4387679102 hasConcept C28328180 @default.
• W4387679102 hasConcept C535046627 @default.
• W4387679102 hasConcept C54355233 @default.
• W4387679102 hasConcept C71924100 @default.
• W4387679102 hasConcept C86803240 @default.
• W4387679102 hasConcept C8891405 @default.
• W4387679102 hasConceptScore W4387679102C10205521 @default.
• W4387679102 hasConceptScore W4387679102C126322002 @default.
• W4387679102 hasConceptScore W4387679102C142724271 @default.
• W4387679102 hasConceptScore W4387679102C159654299 @default.
• W4387679102 hasConceptScore W4387679102C159912055 @default.
• W4387679102 hasConceptScore W4387679102C167672396 @default.
• W4387679102 hasConceptScore W4387679102C168563851 @default.
• W4387679102 hasConceptScore W4387679102C203014093 @default.
• W4387679102 hasConceptScore W4387679102C204787440 @default.
• W4387679102 hasConceptScore W4387679102C22070199 @default.
• W4387679102 hasConceptScore W4387679102C27081682 @default.
• W4387679102 hasConceptScore W4387679102C28328180 @default.
• W4387679102 hasConceptScore W4387679102C535046627 @default.
• W4387679102 hasConceptScore W4387679102C54355233 @default.
• W4387679102 hasConceptScore W4387679102C71924100 @default.
• W4387679102 hasConceptScore W4387679102C86803240 @default.
• W4387679102 hasConceptScore W4387679102C8891405 @default.
• W4387679102 hasLocation W43876791021 @default.
• W4387679102 hasOpenAccess W4387679102 @default.
• W4387679102 hasPrimaryLocation W43876791021 @default.
• W4387679102 hasRelatedWork W127140033 @default.
• W4387679102 hasRelatedWork W1992999743 @default.
• W4387679102 hasRelatedWork W2015095588 @default.
• W4387679102 hasRelatedWork W2027999423 @default.
• W4387679102 hasRelatedWork W2041201944 @default.
• W4387679102 hasRelatedWork W2064440970 @default.
• W4387679102 hasRelatedWork W2132735695 @default.
• W4387679102 hasRelatedWork W2362506364 @default.
• W4387679102 hasRelatedWork W2398341294 @default.
• W4387679102 hasRelatedWork W42562563 @default.

• next